News & Events

LE&RN heads to D.C. with over 140 advocates; support our efforts from home

LE&RN heads to D.C. with over 140 advocates; support our efforts from home

Dear LE&RN Supporting Members and Advocates,

This week, over 140 advocates from across the United States will descend on Washington, D.C., to muster legislative support for increased funding of lymphatic research at NIH and the DoD. We will meet with the Veterans Administration to discuss the situation of veterans who are in need of lymphedema prevention and care. We will build upon our success of working with the CDC to create a lymphedema-focused website and will be requesting that they fund a targeted lymphedema educational campaign. And we will advocate for the Lymphedema Treatment Act (LTA), which has been reintroduced in Congress.

If you are not currently registered and cannot be there in person (registration for Lobby Day is closed), follow LE&RN on Facebook and Twitter, where we will post updates. And contact your representatives in D.C. Tell them you support LE&RN's legislative agenda and that you support LE&RN's Lobby Day participants.

On March 28, LE&RN Spokesperson Kathy Bates, Tim Padera, Ph.D. (Harvard), Veteran Kelly Bell, and I will meet with Senators Dick Durbin (IL), Tom Cole (OK), Todd Young (PA), Ed Markey (MA) and Rep. Ted Lieu (CA), all of whom are on key committees overseeing LE&RN's agenda.

That evening, MediUSA and ImpediMed will sponsor a reception at a Washington hotel, hosted by Ms. Bates. The 100+ attendees include our advocates, legislative staff, and staff from the National Institutes of Health (NIH).

On March 30, LE&RN will have its second annual DC Walk and Rally on the steps of the Lincoln Memorial. It's not too late to join us. Registration is quick and easy at Or you can register the morning of the event on site. If you cannot make it in person, consider making a donation to a fundraising team. 

Thank you for your support as we bring this important fight to our nation's capital.


William Repicci
President & CEO, LE&RN